Since recent reviews have highlighted the pivotal role of podocytes in the progression of Diabetic Nephropathy (Carney, 2017; Dai et al., 2017), we asked whether we could employ podometric methodology using transducin-like enhancer of split 4 (TLE4) as a nuclear podocyte-specific marker, and glomerular epithelial protein-1 (GLEPP1), a glomerular marker to quantify podocyte density in Diabetic Nephropathy tissue, and further assess the same cohort for expression and localization of YAP. Here, PTPRO is linked to diabetic kidney disease.